Technical Analysis for OCUP - Ocuphire Pharma, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 1.93 | 1.58% | 0.03 |
Earnings due: Mar 28
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Boomer Sell Setup | Bearish Swing Setup | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Calm After Storm | Range Contraction | 1.58% | |
Lower Bollinger Band Walk | Weakness | 1.58% | |
Inside Day | Range Contraction | 1.58% | |
Wide Bands | Range Expansion | 1.58% | |
Lower Bollinger Band Touch | Weakness | 1.58% | |
Oversold Stochastic | Weakness | 1.58% |
Alert | Time |
---|---|
Possible NR7 | about 19 hours ago |
Up 3% | about 22 hours ago |
60 Minute Opening Range Breakout | about 22 hours ago |
Up 2% | about 22 hours ago |
Lower Bollinger Band Support | about 23 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 03/28/2024
Ocuphire Pharma, Inc. Description
Ocuphire is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances, pharmacologically-induced mydriasis, and presbyopia. Ocuphire’s second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation, and commercialization of drugs in key global markets.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Diabetes Eye Inflammation Ophthalmology Ophthalmic Vascular Disease Vision Macular Edema Diabetic Retinopathy Retina Diabetic Macular Edema Blindness Retinopathy Molecule Product Angiogenesis Night Vision Presbyopia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 6.6 |
52 Week Low | 1.85 |
Average Volume | 200,398 |
200-Day Moving Average | 3.30 |
50-Day Moving Average | 2.59 |
20-Day Moving Average | 2.33 |
10-Day Moving Average | 2.12 |
Average True Range | 0.15 |
RSI (14) | 29.08 |
ADX | 38.0 |
+DI | 6.81 |
-DI | 34.41 |
Chandelier Exit (Long, 3 ATRs) | 2.26 |
Chandelier Exit (Short, 3 ATRs) | 2.30 |
Upper Bollinger Bands | 2.83 |
Lower Bollinger Band | 1.82 |
Percent B (%b) | 0.11 |
BandWidth | 43.60 |
MACD Line | -0.19 |
MACD Signal Line | -0.14 |
MACD Histogram | -0.0461 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.11 | ||||
Resistance 3 (R3) | 2.11 | 2.05 | 2.08 | ||
Resistance 2 (R2) | 2.05 | 2.00 | 2.05 | 2.07 | |
Resistance 1 (R1) | 1.99 | 1.98 | 2.02 | 1.99 | 2.06 |
Pivot Point | 1.93 | 1.93 | 1.95 | 1.93 | 1.93 |
Support 1 (S1) | 1.87 | 1.88 | 1.90 | 1.87 | 1.80 |
Support 2 (S2) | 1.81 | 1.86 | 1.81 | 1.79 | |
Support 3 (S3) | 1.75 | 1.81 | 1.78 | ||
Support 4 (S4) | 1.75 |